Researchers at the University of Birmingham, UK, are collaborating with scientists from China’s Guangzhou Institutes of Biomedicine and Health (GIBH) to develop new medicines for treating global epidemics.

The university’s team has discovered multiple compounds with potential as therapeutics and its technology transfer company University of Birmingham Enterprise hopes that the partnership with Chinese scientists will lead to development of new drugs to tackle infectious diseases.

University of Birmingham synthetic chemistry reader John Fossey and Birmingham Drug Discovery Facility director Luke Alderwick led a team that designed chemistry for the identified drug candidates.

Subsequently, experts at GIBH will design and synthesise new molecules that would feature ‘better drug-like’ properties. Both the partners will then test the biological activity of the resulting molecules.

“University of Birmingham are collaborating with GIBH to develop new medicines for treating global epidemics.”

The process is expected to be sped up by data sharing through the University of Birmingham’s BEAR DataShare facility, which was established to allow secure project-related data sharing globally.

The British university has a long-standing relationship with the Chinese city of Guangzhou; it opened its Guangzhou Centre in 2011 and its China Institute has forged close linked with partners in the city and beyond.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Last month the university launched its spin off company, called Viatem, to explore the therapeutic potential of peptide inhibitor of trans-endothelial migration (PEPITEM) for rheumatoid arthritis.

PEPITEM Is a 14 amino acid peptide and mediator in the andiponectin pathway, which controls the recruitment of immune cells into inflamed tissues.